Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8217779 | 0.83 | CHRNB2 (0.50) | FDPSCHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL2420469 | 0.81 | FDPS (0.53) | FDPSCHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL7288023 | 0.81 | CHRNA7 (0.53) | FDPSCHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL14732858 | 0.81 | FDPS (0.53) | FDPSCHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL19737206 | 0.81 | CHRNA7 (0.53) | FDPSCHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL20353168 | 0.81 | FDPS (0.51) | FDPSCHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL103883 | 0.80 | FDPS (0.55) | FDPSCHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL18934268 | 0.80 | TDP1 (0.51) | FDPSCHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL12282852 | 0.79 | FDPS (0.46) | FDPSCHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL22095939 | 0.79 | CYP2D6 (0.55) | FDPSCHRNB2CHRNA4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | FDPS 1316/4885CHRNB2 870/4885CHRNA4 1138/4885 |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | FDPS 1316/4885CHRNB2 870/4885CHRNA4 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.